Skip to NavigationSkip to content

News

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the treatment of...
AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it from its rivals, after...
With in-depth features on mobile health, clinical trials and Brexit, and the future of patient-reported outcomes, as well as interviews with Amicus...
Shares in Prothena have dropped by close to 70% on the news that two of its trials into its lead drug candidate, NEOD001, had both missed the mark.
Novartis will expand its current partnership with Pear Therapeutics, as it reveals that its generic and biologics arm Sandoz will work with the...
Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its $1 billion drug development deal...
AB Science has revealed that the European Medicines Agency’s CHMP has adopted a negative opinion of masitinib in the treatment of amyotrophic...
Fresenius has announced its intention to terminate the merger agreement with Akorn, over the $4.75 billion deal that the two companies had sealed in...
After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis, MPs have now written to the...
It's the end of another week and there's really been one story that has dominated the headlines – Takeda’s potential takeover of Shire. It should...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches